The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
SPARK has extended its influence to an additional 9.47 million students worldwide
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
The company announced positive topline data from the Phase 3 ADorable-1 trial
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Subscribe To Our Newsletter & Stay Updated
